Wellington Management Group LLP Purchases 23,660 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Wellington Management Group LLP increased its stake in Centessa Pharmaceuticals by 20.6%, now holding 138,767 shares valued at approximately $1.99 million.
• In a recent transaction, insider Iqbal J. Hussain sold 12,000 shares for $168,240, indicating a 10.22% decrease in his position.
• Analysts have mixed ratings on Centessa Pharmaceuticals, with price targets ranging from $30.00 to $40.00 and a consensus rating of "Buy".

Wellington Management Group LLP raised its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 20.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,767 shares of the company's stock after purchasing an additional 23,660 shares during the quarter. Wellington Management Group LLP owned 0.10% of Centessa Pharmaceuticals worth $1,995,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of CNTA. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 1,509.6% during the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after purchasing an additional 57,925 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. OMERS ADMINISTRATION Corp acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $171,000. Cerity Partners LLC acquired a new position in Centessa Pharmaceuticals during the first quarter valued at approximately $471,000. Finally, American Century Companies Inc. boosted its position in Centessa Pharmaceuticals by 1.2% during the first quarter. American Century Companies Inc. now owns 1,092,754 shares of the company's stock valued at $15,714,000 after purchasing an additional 13,046 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price target for the company. Wells Fargo & Company assumed coverage on Centessa Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $31.00 price target for the company. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They set an "outperform" rating and a $40.00 target price for the company. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $31.45.

Insider Activity at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $12.63, for a total value of $694,650.00. Following the completion of the transaction, the chief executive officer directly owned 221,017 shares in the company, valued at approximately $2,791,444.71. The trade was a 19.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the transaction, the insider directly owned 122,279 shares of the company's stock, valued at approximately $1,694,786.94. This trade represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock valued at $2,472,814 over the last ninety days. 7.09% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded down $0.13 during midday trading on Thursday, reaching $15.78. 550,875 shares of the company's stock traded hands, compared to its average volume of 970,754. The company has a 50-day moving average price of $15.88 and a two-hundred day moving average price of $14.47. The firm has a market capitalization of $2.11 billion, a PE ratio of -8.84 and a beta of 1.47. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.